Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.66 |
| ▸ | CA9 | Q16790 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27945133 | 0.98 | NPC1 (0.63) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL180384 | 0.85 | NPC1 (0.73) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL1620582 | 0.83 | NPC1 (0.60) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL1796011 | 0.83 | NPC1 (0.60) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL3095761 | 0.83 | NPC1 (0.70) | NPC1RAB9ACA12CA9KMT2A | |
| Hydrochloric Acid SCHEMBL11786759 | 0.83 | NPC1 (0.70) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL7135592 | 0.81 | NPC1 (0.79) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL425164 | 0.81 | NPC1 (0.68) | NPC1RAB9ACA12CA9KMT2A | |
| Carbamic Acid SCHEMBL30426064 | 0.81 | ALDH1A1 (0.74) | NPC1RAB9ACA12CA9KMT2A | |
| Urea SCHEMBL28073648 | 0.81 | ALDH1A1 (0.74) | NPC1RAB9ACA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725238-A4 | M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | claimed |
| EP-1725238-A2 | M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | claimed |
| US-7081481-B2 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY (US) | 2006-07-25 | — | — | US | claimed |
| WO-2005094251-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | claimed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | claimed |
| US-20040102521-A1 | Excitatory amino acid receptor modulators | ELI LILLY AND COMPANY | 2004-05-27 | — | — | US | claimed |
| EP-1289940-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | claimed |
| EP-0923933-B1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | SEARLE & CO (US) | 2002-07-03 | — | — | EP | claimed |
| WO-2001092213-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2001-12-06 | — | — | WO | claimed |
| EP-0923933-A1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | G.D. SEARLE & CO. (US) | 1999-06-23 | — | — | EP | claimed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | claimed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-115837174-A | Organogel or liquid chromatography | F·帕尔芒捷 | 2023-03-24 | — | — | CN | disclosed |
| WO-2022081984-A1 | METHODS AND COMPOUNDS TO TREAT SARS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-0083096-B1 | PRODUCTION OF URETHANE COMPOUNDS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-02-25 | — | — | EP | disclosed |
| US-4621149-A | PLATINUM GROUP METAL HALOGEN OR HALOGEN COMPOUND | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-11-04 | — | — | US | disclosed |
| EP-0083096-A2 | Production of urethane compounds | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102521-A1 | Excitatory amino acid receptor modulators | GRM1, GRM2, GRIN1 | NPC1 1241/4885RAB9A 2180/4885CA12 2447/4885 |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | NPC1 4574/4885RAB9A 3412/4885CA12 4454/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | NPC1 3253/4885RAB9A 3911/4885CA12 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.